HighVista Strategies’s Edgewise Therapeutics EWTX Stock Holding History

HighVista Strategies’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.7M	Sell	90,996 -935	-1%	-$32.2K	0.84%	38
2026 Q1	$2.9M	Sell	91,931 -79,206	-46%	-$2.28M	0.8%	40
2025 Q4	$4.25M	Sell	171,137 -36,964	-18%	-$742K	1.09%	29
2025 Q3	$3.38M	Buy	208,101 +138,378	+198%	+$1.96M	0.83%	33
2025 Q2	$914K	Sell	69,723 -21,484	-24%	-$310K	0.34%	113
2025 Q1	$2.01M	Buy	91,207 +8,475	+10%	+$222K	0.77%	38
2024 Q4	$2.21M	Sell	82,732 -6,106	-7%	-$194K	0.82%	37
2024 Q3	$2.37M	Buy	+88,838	New	+$1.77M	0.82%	36
2023 Q1	–	Sell	-187,480	Closed	-$1.68M	–	115
2022 Q4	$1.68M	Buy	187,480 +84,018	+81%	+$788K	1%	32
2022 Q3	$1.02M	Hold	103,462	–	–	0.58%	41
2022 Q2	$824K	Buy	103,462 +43,729	+73%	+$331K	0.5%	43
2022 Q1	$579K	Buy	+59,733	New	+$769K	0.37%	67
2021 Q4	–	Sell	-39,133	Closed	-$650K	–	86
2021 Q3	$650K	Buy	39,133 +11,666	+42%	+$211K	0.43%	65
2021 Q2	$586K	Buy	+27,467	New	+$751K	0.42%	68

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighVista Strategies's EWTX Position: Q2 2026 in Review

HighVista Strategies reduced its Edgewise Therapeutics (EWTX) stake by 1% in Q2 2026, selling an estimated $32.2K and leaving 90,996 shares worth $3.7M. The position accounts for 0.84% of the portfolio, ranked #38.

HighVista Strategies first reported a position in EWTX in Q2 2021 and has held it in 14 quarters since. The position peaked at $4.25M in Q4 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

HighVista Strategies held 90,996 shares of Edgewise Therapeutics worth $3.7M as of Q2 2026.
HighVista Strategies sold 935 Edgewise Therapeutics shares in Q2 2026, an estimated $32.2K.
Edgewise Therapeutics made up 0.84% of HighVista Strategies's portfolio in Q2 2026, its #38 holding.
HighVista Strategies first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 14 quarters since.
HighVista Strategies's Edgewise Therapeutics position peaked at $4.25M in Q4 2025.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.